Novo’s oral semaglutide bests Lilly and Boehringer Ingelheim’s Jardiance in phase 3, but questions remain
Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral [...]
Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral [...]